These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15201942)

  • 41. Clinical and radiological effects of anakinra in patients with rheumatoid arthritis.
    Bresnihan B; Cobby M
    Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii22-8. PubMed ID: 12817092
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Interleukin-1 receptor antagonists in the treatment rheumatoid arthritis].
    Zoń-Giebel A; Kotulska A; Giebel S; Cader SA; Kucharz EJ
    Przegl Lek; 2002; 59(11):916-8. PubMed ID: 12715722
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis.
    Chen DY; Chou SJ; Hsieh TY; Chen YH; Chen HH; Hsieh CW; Lan JL
    J Formos Med Assoc; 2009 Apr; 108(4):310-9. PubMed ID: 19369178
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial.
    Fleischmann RM; Schechtman J; Bennett R; Handel ML; Burmester GR; Tesser J; Modafferi D; Poulakos J; Sun G
    Arthritis Rheum; 2003 Apr; 48(4):927-34. PubMed ID: 12687534
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis.
    Schiff MH
    Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i103-8. PubMed ID: 11053099
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis.
    Bendele AM; Chlipala ES; Scherrer J; Frazier J; Sennello G; Rich WJ; Edwards CK
    Arthritis Rheum; 2000 Dec; 43(12):2648-59. PubMed ID: 11145022
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy.
    Kremer JM; Emery P; Camp HS; Friedman A; Wang L; Othman AA; Khan N; Pangan AL; Jungerwirth S; Keystone EC
    Arthritis Rheumatol; 2016 Dec; 68(12):2867-2877. PubMed ID: 27389975
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents.
    Fleishmann RM
    Clin Exp Rheumatol; 2002; 20(5 Suppl 27):S35-41. PubMed ID: 14989428
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anakinra for rheumatoid arthritis.
    Mertens M; Singh JA
    Cochrane Database Syst Rev; 2009 Jan; (1):CD005121. PubMed ID: 19160248
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
    Bingham CO; Mendelsohn AM; Kim L; Xu Z; Leu J; Han C; Lo KH; Westhovens R; Weinblatt ME;
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1627-36. PubMed ID: 25623393
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
    Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
    Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis.
    Cunnane G; Madigan A; Murphy E; FitzGerald O; Bresnihan B
    Rheumatology (Oxford); 2001 Jan; 40(1):62-9. PubMed ID: 11157143
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis.
    Bao J; Yue T; Liu W; Zhang Q; Zhou L; Xu HJ; Dai SM
    Clin Rheumatol; 2011 May; 30(5):697-701. PubMed ID: 21221689
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of the impact of Tripterygium wilfordii Hook F and Methotrexate treatment on radiological progression in active rheumatoid arthritis: 2-year follow up of a randomized, non-blinded, controlled study.
    Zhou YZ; Zhao LD; Chen H; Zhang Y; Wang DF; Huang LF; Lv QW; Liu B; Li Z; Wei W; Li H; Liao X; Liu H; Liu X; Jin H; Wang J; Fei YY; Wu QJ; Zhang W; Shi Q; Zheng WJ; Zhang FC; Tang FL; Lipsky PE; Zhang X
    Arthritis Res Ther; 2018 Apr; 20(1):70. PubMed ID: 29636089
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
    Westhovens R; Taylor PC; Alten R; Pavlova D; Enríquez-Sosa F; Mazur M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
    Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 57. IL-1 inhibitors: novel agents in the treatment of rheumatoid arthritis.
    Gabay C
    Expert Opin Investig Drugs; 2000 Jan; 9(1):113-27. PubMed ID: 11060665
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preventing joint damage as the best measure of biologic drug therapy.
    Bresnihan B
    J Rheumatol Suppl; 2002 Sep; 65():39-43. PubMed ID: 12236622
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Niclosamide as an adjuvant to etanercept in treatment patients with active rheumatoid arthritis: an 8-week randomized controlled pilot study.
    Al-Gareeb AIA; Gorial FI; Mahmood AS
    Clin Rheumatol; 2018 Oct; 37(10):2633-2641. PubMed ID: 29882203
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
    Kremer JM; Cohen S; Wilkinson BE; Connell CA; French JL; Gomez-Reino J; Gruben D; Kanik KS; Krishnaswami S; Pascual-Ramos V; Wallenstein G; Zwillich SH
    Arthritis Rheum; 2012 Apr; 64(4):970-81. PubMed ID: 22006202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.